Oncogenetics Group
The Oncogenetics group have three sub-teams working alongside each other: the lab group of scientists and clinical fellows, the data group of scientists and administrators and the clinical group of nurses and clinical fellows. Our principal investigator, Professor Ros Eeles, oversees these groups.
Professor Rosalind Eeles
Group Leader:
Oncogenetics
Professor Rosalind Eeles is searching for genetic variants that increase a person’s risk of prostate cancer and is currently leading clinical trials looking into whether regular screening of men with certain genetic mutations/genetic risk profiles leads to earlier diagnosis.
Researchers in this group
.
Professor Rosalind Eeles's group have written 50 publications
Most recent new publication 1/11/2008
See all their publicationsResearch, projects and publications in this group
The Oncogenetics Group aims to translate laboratory findings about genetic risk factors for cancer into the clinic. Our focus is on predisposition to prostate cancer. The laboratory component of the research programme involves the search for prostate cancer predisposition genes and studies of their mutation spectra, risks and interactions with environmental factors.
The clinical component of the research includes risk profiling, targeted screening, prevention and the application of cancer genetics to cancer management. There is close interaction with The Royal Marsden NHS Foundation Trust and, in addition to studies in the management of individuals with a predisposition to prostate cancer, there is a research programme in genetic counselling and integration of cancer genetics into the cancer care pathway extending all the way from primary to tertiary care. We have established collaborations with primary care to effect studies in the community.
We have established a uro-genetics clinic to investigate the application of genetic research in prostate cancer predisposition to the clinic. This is in addition to specialised prostate cancer predisposition risk clinic for the translational research into and management of men with mutations in the genes BRCA1, BRCA2 and Lynch Syndrome. The prostate cancer risk clinic will shortly be expanded to include new studies in genetic panel testing and its application.
The group also coordinates a number of psychosocial studies evaluating the impact of genetics and screening on men at high risk of prostate cancer.
The Institute of Cancer Research in collaboration with The Royal Marsden NHS Foundation Trust.
With funding from:
- Cancer Research UK
- Movember
- National Institute for Health Research
- European Research Council
- The Ronald and Rita McAulay Foundation
- The de Laszlo Trust
- The Peacock Trust
- The Oppenheimer Foundation
- The Patrick Evans Trust
News and discoveries from this group
£1.5m AI and genetics project to find men with deadliest prostate cancers early
Prostate cancer spit test could save the NHS £500 million a year
ASCO 2024: Prostate cancer spit test better for men with high genetic risk than standard blood test
